ZA202101688B - Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain - Google Patents

Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain

Info

Publication number
ZA202101688B
ZA202101688B ZA2021/01688A ZA202101688A ZA202101688B ZA 202101688 B ZA202101688 B ZA 202101688B ZA 2021/01688 A ZA2021/01688 A ZA 2021/01688A ZA 202101688 A ZA202101688 A ZA 202101688A ZA 202101688 B ZA202101688 B ZA 202101688B
Authority
ZA
South Africa
Prior art keywords
treatment
joint pain
pharmaceutical compositions
compositions suitable
articular delivery
Prior art date
Application number
ZA2021/01688A
Other languages
English (en)
Inventor
Tseng Yun-Long
Shih Sheue-Fang
Chang Po-Chun
Chang Lo
Original Assignee
Tlc Biopharmaceuticals Inc
Taiwan Liposome Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tlc Biopharmaceuticals Inc, Taiwan Liposome Co Ltd filed Critical Tlc Biopharmaceuticals Inc
Publication of ZA202101688B publication Critical patent/ZA202101688B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2021/01688A 2018-09-16 2021-03-12 Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain ZA202101688B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731941P 2018-09-16 2018-09-16
PCT/US2019/051247 WO2020056399A1 (en) 2018-09-16 2019-09-16 Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain

Publications (1)

Publication Number Publication Date
ZA202101688B true ZA202101688B (en) 2024-06-26

Family

ID=68084954

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/01688A ZA202101688B (en) 2018-09-16 2021-03-12 Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain

Country Status (15)

Country Link
US (1) US12208104B2 (https=)
EP (1) EP3849522A1 (https=)
JP (1) JP7634476B2 (https=)
KR (1) KR20210060559A (https=)
CN (1) CN112702993A (https=)
AU (1) AU2019339528B2 (https=)
BR (1) BR112021004880A2 (https=)
CA (1) CA3112234A1 (https=)
CL (1) CL2021000627A1 (https=)
IL (1) IL281513A (https=)
MX (1) MX2021003030A (https=)
SG (1) SG11202102400PA (https=)
TW (1) TWI843751B (https=)
WO (1) WO2020056399A1 (https=)
ZA (1) ZA202101688B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3187955A1 (en) 2020-08-05 2022-02-10 Sheue-Fang Shih Pharmaceutical composition of intra-articular corticosteroid for pain control
WO2024230404A1 (zh) * 2023-05-05 2024-11-14 中南大学湘雅医院 一种治疗关节疼痛的氢氧化镁纳米粒、其制备方法及应用
TW202519194A (zh) * 2023-11-03 2025-05-16 台灣微脂體股份有限公司 用於疼痛控制之關節內皮質類固醇的微脂體組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152962A1 (en) * 2002-06-12 2005-07-14 Metselaar Josbert M. Composition for treatment of inflammatory disorders
EP1371362A1 (en) * 2002-06-12 2003-12-17 Universiteit Utrecht Holding B.V. Composition for treatment of inflammatory disorders
DK2797601T3 (en) 2012-02-10 2018-06-14 Taiwan Liposome Co Ltd PHARMACEUTICAL COMPOSITIONS FOR REDUCING COMPLICATIONS BY Ocular steroid
RU2677658C2 (ru) * 2012-07-05 2019-01-18 Тайвэн Липосом Ко, Лтд. Способы лечения артрита

Also Published As

Publication number Publication date
TWI843751B (zh) 2024-06-01
JP7634476B2 (ja) 2025-02-21
US20210338688A1 (en) 2021-11-04
CL2021000627A1 (es) 2021-09-10
BR112021004880A2 (pt) 2021-06-01
IL281513A (en) 2021-04-29
SG11202102400PA (en) 2021-04-29
CN112702993A (zh) 2021-04-23
WO2020056399A1 (en) 2020-03-19
US12208104B2 (en) 2025-01-28
JP2022500364A (ja) 2022-01-04
TW202023569A (zh) 2020-07-01
MX2021003030A (es) 2021-05-27
AU2019339528A1 (en) 2021-04-15
AU2019339528B2 (en) 2025-01-30
CA3112234A1 (en) 2020-03-19
KR20210060559A (ko) 2021-05-26
EP3849522A1 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
PH12021551792A1 (en) Bi-ligand drug conjugate and use thereof
NZ777871A (en) Small molecule modulators of il-17
MX2024001204A (es) Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con derivados de aceite de pescado para usarse en tratar enfermedades del higado graso.
ZA202101688B (en) Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
EA200870469A1 (ru) Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
UA98462C2 (ru) Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
ZA202000028B (en) Use of vibegron to treat overactive bladder
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
TW200603816A (en) Risedronate compositions and their methods of use
IL272036B1 (en) Methods and compositions for treatment of pain using capsaicin
HRP20240812T1 (hr) Oblici doziranja i terapijska primjena l-4-klorokinurenina
EP4389218A3 (en) Composition for treating joint disease and kit containing same
PH12022551043A1 (en) Combination of a cxcr7 antagonist with an s1p1 receptor modulator
BR112014001503A2 (pt) composições farmacêuticas compreendendo 4-bromo-n-(imidazolidin-2-ilideno)-1h-benzimidazol-5-amina para o tratamento de doenças de pele
ZA202200331B (en) Naltrexone formulation
ZA202100604B (en) Methods to reduce complications of intra-articular steroid
PH12020551493A1 (en) Triazacyclododecansulfonamide (``tcd``)-based protein secretion inhibitors
WO2018136647A3 (en) Therapeutic use of beta-lactams in hematopoiesis, immuno-oncology therapy, and regulation of lipoprotein and apolipoprotein levels
EA202092944A1 (ru) Применение пероральных распадающихся таблеток рилузола для лечения заболеваний
NZ767242A (en) Growth differentiation factor 15 agonist compounds and methods of using the same
AR120453A1 (es) Combinación de un inhibidor de btk y un inhibidor de mdm2 para el tratamiento del cáncer